# A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease

> **NCT01635621** · PHASE2 · WITHDRAWN · sponsor: **UCB BIOSCIENCES GmbH**

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Olokizumab (OKZ)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01635621
- **Lead sponsor:** UCB BIOSCIENCES GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-06
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was withdrawn due to delay in timelines. There were no safety concerns regarding the study or the compound in the decision to withdraw the trial.
- **Last updated:** 2012-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01635621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01635621, "A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01635621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*